Harrow, Inc. (NASDAQ:HROW) Position Boosted by Creative Planning

Creative Planning lifted its stake in Harrow, Inc. (NASDAQ:HROW) by 96.8% in the second quarter, Holdings Channel.com reports. The firm owned 29,486 shares of the company’s stock after acquiring an additional 14,500 shares during the quarter. Creative Planning’s holdings in Harrow were worth $616,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in HROW. nVerses Capital LLC acquired a new stake in shares of Harrow during the 2nd quarter valued at $33,000. Allspring Global Investments Holdings LLC grew its stake in shares of Harrow by 2,730.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after buying an additional 2,048 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Harrow by 66.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,745 shares of the company’s stock worth $89,000 after buying an additional 2,682 shares during the last quarter. Bayesian Capital Management LP acquired a new position in Harrow in the first quarter worth approximately $185,000. Finally, Price T Rowe Associates Inc. MD raised its position in Harrow by 6.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock valued at $221,000 after acquiring an additional 1,033 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Up 2.1 %

HROW stock opened at $50.71 on Monday. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -55.73 and a beta of 0.75. The company has a 50-day moving average of $41.55 and a two-hundred day moving average of $25.78. Harrow, Inc. has a 52-week low of $7.60 and a 52-week high of $52.45. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.60 and a quick ratio of 2.43.

Harrow (NASDAQ:HROW) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.12. The firm had revenue of $48.94 million during the quarter, compared to analysts’ expectations of $42.78 million. Harrow had a negative net margin of 21.78% and a negative return on equity of 40.59%. As a group, equities research analysts anticipate that Harrow, Inc. will post -0.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Craig Hallum upped their price objective on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 4th. Lake Street Capital increased their price objective on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a report on Friday, October 4th. Finally, B. Riley restated a “buy” rating and issued a $50.00 target price on shares of Harrow in a report on Thursday, August 29th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.